Zoetis Inc (N:ZTS)
Business Focus: Veterinary Drugs
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 10 Sylvan Way PARSIPPANY NJ 07054 |
| Tel: | N/A |
| Website: | https://www.zoetis.com |
| IR: | See website |
| Key People | ||
| Kristin C. Peck Chief Executive Officer, Director | Robert J. Polzer Executive Vice President, President - Research and Development | Wetteny N. Joseph Chief Financial Officer, Executive Vice President |
| Roxanne Lagano Executive Vice President, Chief Human Resource Officer, Global Operations, Interim General Counsel, Corporate Secretary | Wafaa Mamilli Executive Vice President, Chief Digital and Technology Officer and Group President - China, Brazil and Precision Animal Health | Nicholas Ashton Executive Vice President, President - Global Manufacturing and Supply |
| Jeannette Ferran Astorga Executive Vice President - Corporate Affairs, Communications, Chief Sustainability Officer | Ester Banque Executive Vice President, President- U.S. Operations | Jamie Brannan Executive Vice President and President, International Operations and Aquaculture | Rimma Driscoll Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices |
| Business Overview |
| Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. It has a diversified business, commercializing products across eight core species: dogs, cats and horses (companion animals) and cattle, swine, poultry, fish and sheep (livestock); and within seven major product categories: parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics and medicated feed additives. The Company operates through two segments: the United States and International. Within each of these segments, it offers a diversified product portfolio for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and its products are sold in more than 100 countries. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Zoetis Inc revenues increased 6% to $8.54B. Net income increased 11% to $2.34B. Revenues reflect US segment increase of 6% to $4.56B, International segment increase of 6% to $3.91B, United States segment increase of 6% to $4.56B, Brazil segment increase of 19% to $393M. Net income benefited from Interest income increase from $50M to $105M (income). |
| Employees: | 14,100 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $74,605M as of Dec 31, 2023 |
| Annual revenue (TTM): | $8,544M as of Dec 31, 2023 |
| EBITDA (TTM): | $3,596M as of Dec 31, 2023 |
| Net annual income (TTM): | $2,344M as of Dec 31, 2023 |
| Free cash flow (TTM): | $929.00M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $4,528M as of Dec 31, 2023 |
| Shares outstanding: | 456,947,205 as of Mar 28, 2024 |
| Index Membership: | S&P 500 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.